REFERENCE
1. Bernard J, Weil M, Jacquillat C. Treatment of acute lymphoblastic
leukemia. N Engl J Med . 2006;354(2):1-11.
doi:10.1056/NEJMRA052603
2. Sallan SE, Hitchcock-Bryan S, Gelber R, Cassady JR, Frei E, Nathan
DG. Influence of Intensive Asparaginase in the Treatment of Childhood
Non-T-Cell Acute Lymphoblastic Leukemia. Cancer Res . 1983;43(11).
3. Clavell LA, Gelber RD, Cohen HJ, et al. Four-Agent Induction and
Intensive Asparaginase Therapy for Treatment of Childhood Acute
Lymphoblastic Leukemia. N Engl J Med . 1986;315(11):657-663.
doi:10.1056/nejm198609113151101
4. Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ.
Comparative pharmacokinetic studies of three asparaginase preparations.J Clin Oncol . 1993;11(9):1780-1786.
doi:10.1200/JCO.1993.11.9.1780
5. Lanvers-Kaminsky C. Asparaginase pharmacology: challenges still to be
faced. Cancer Chemother Pharmacol 2017 793 . 2017;79(3):439-450.
doi:10.1007/S00280-016-3236-Y
6. Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of
native Escherichia coli asparaginase and polyethylene glycol conjugated
asparaginase for treatment of children with newly diagnosed
standard-risk acute lymphoblastic leukemia: A Children’s Cancer Group
study. Blood . 2002;99(6):1986-1994. doi:10.1182/blood.V99.6.1986
7. Silverman LB, Supko JG, Stevenson KE, et al. Intravenous
PEG-asparaginase during remission induction in children and adolescents
with newly diagnosed acute lymphoblastic leukemia. Blood .
2010;115(7):1351-1353. doi:10.1182/BLOOD-2009-09-245951
8. Rizzari C, Asselin B. Asparaginase pharmacokinetics and implications
of therapeutic drug monitoring. Leuk Lymphoma .
2015;56(8):2273-2280. doi:10.3109/10428194.2014.1003056
9. Brigitha LJ, Pieters R, van der Sluis IM. How much asparaginase is
needed for optimal outcome in childhood acute lymphoblastic leukaemia? A
systematic review. Eur J Cancer . 2021;157:238-249.
doi:10.1016/J.EJCA.2021.08.025
10. Vora A, Wade R, Mitchell C, Goulden N, Richards S. Efficacy and
Toxicity of Pegylated Asparaginase in the Treatment of Children and
Young Adults with Acute Lymphoblastic Leukaemia: Results of the United
Kingdom Medical Research Council (MRC) Trial UKALL 2003. Blood .
2008;112(11):909-909. doi:10.1182/BLOOD.V112.11.909.909
11. Dinndorf PA, Gootenberg J, Cohen MH, Keegan P, Pazdur R. FDA Drug
Approval Summary: Pegaspargase (Oncaspar) for the First-Line Treatment
of Children with Acute Lymphoblastic Leukemia (ALL).
doi:10.1634/theoncologist.12-8-991
12. Place AE, Stevenson KE, Vrooman LM, et al. Intravenous pegylated
asparaginase versus intramuscular native Escherichia coli l-asparaginase
in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI
05-001): a randomised, open-label phase 3 trial. Lancet Oncol .
2015;16(16):1677-1690. doi:10.1016/S1470-2045(15)00363-0
13. Cooper SL, Young DJ, Bowen CJ, Arwood NM, Poggi SG, Brown PA.
Universal premedication and therapeutic drug monitoring for
asparaginase-based therapy prevents infusion-associated acute adverse
events and drug substitutions. Pediatr Blood Cancer .
2019;66(8):e27797. doi:10.1002/PBC.27797
14. Kloos RQH, Pieters R, Jumelet FMV, De Groot-Kruseman HA, Van Den Bos
C, Van Der Sluis IM. Individualized asparaginase dosing in childhood
acute lymphoblastic leukemia. J Clin Oncol . 2020;38(7):715-724.
doi:10.1200/JCO.19.02292
15. Sankaran H, Sengupta S, Purohit V, et al. A comparison of
asparaginase activity in generic formulations of E.coli derived L-
asparaginase: In-vitro study and retrospective analysis of asparaginase
monitoring in pediatric patients with leukemia. Br J Clin
Pharmacol . 2020;86(6):1081-1088. doi:10.1111/bcp.14216
16. Sidhu J, Gogoi MP, Agarwal P, et al. Unsatisfactory quality of E.
coli asparaginase biogenerics in India: Implications for clinical
outcomes in acute lymphoblastic leukaemia. Pediatr Blood Cancer .
2021;68(11). doi:10.1002/PBC.29046
17. Vyas C, Jain S, Kapoor G, Mehta A, Takkar Chugh P. Experience with
generic pegylated L-asparaginase in children with acute lymphoblastic
leukemia and monitoring of serum asparaginase activity. Pediatr
Hematol Oncol . 2018;35(5-6):331-340. doi:10.1080/08880018.2018.1538277
18. Hijiya N, Van Der Sluis IM. Asparaginase-associated toxicity in
children with acute lymphoblastic leukemia. Leuk Lymphoma .
2016;57(4):748-757. doi:10.3109/10428194.2015.1101098
19. Gupta S, Wang C, Raetz EA, et al. Impact of asparaginase
discontinuation on outcome in childhood acute lymphoblastic leukemia: A
report from the children’s oncology group. J Clin Oncol .
2020;38(17):1897-1905. doi:10.1200/JCO.19.03024
20. Gibson A, Hernandez C, Tejada FNH, Kawedia J, Rytting M, Cuglievan
B. Asparaginase-Associated Pancreatitis in Pediatric Patients with Acute
Lymphoblastic Leukemia: Current Perspectives. Paediatr Drugs .
2021;23(5):457-463. doi:10.1007/S40272-021-00463-1